3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Terminated
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Dermatologic
2
Conditions
Neoplasms
2
Mycosis Fungoides
2
Lymphoproliferative Disorders
2
Lymphoma, T-Cell, Cutaneous
2
Lymphoma, T-Cell
2
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Lymphatic Diseases
2
Immunoproliferative Disorders
2
Immune System Diseases
2
Interventions
Cyclophosphamide
4
Prednisone
3
Lenalidomide
3
fludarabine phosphate
2
etoposide phosphate
2
cobomarsen
2
Whole-Body Irradiation
2
Vorinostat
2
Vincristine
2
Stem Cell Transplantation
2
Nivolumab
2
Melphalan
2
Granulocyte Colony-Stimulating Factor
2
Filgrastim
2
Etoposide
2
Doxorubicin
2
Bortezomib
2
Alemtuzumab
2
tazemetostat
1
sargramostim
1
romidepsin
1
poly ICLC
1
plerixafor
1
pegylated granulocyte colony-stimulating factor, human
1
pegfilgrastim
1
pegaspargase
1
liposomal doxorubicin
1
forodesine
1
fludarabine
1
duvelisib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Terminated
×
Lymphoma, T-Cell
×
cobomarsen
×
Clear all
NCT03713320
2022-04-08
SOLAR
miRagen Therapeutics, Inc.
Phase 2
Terminated
37 enrolled
23 charts
NCT03837457
2020-11-19
PRISM
miRagen Therapeutics, Inc.
Phase 2
Terminated
8 enrolled